11.05.2017 • NewsPeopleLanxessChemtura

Stephen Forsyth to Become Chief Integration Officer at Lanxess

Stephen C. Forsyth is to become the new Chief Integration Officer of Lanxess....
Stephen C. Forsyth is to become the new Chief Integration Officer of Lanxess. © Lanxess

German specialty chemicals producer Lanxess has named Stephen C. Forsyth (61) as the future Chief Integration Officer responsible for integrating the Chemtura businesses into the Cologne-based company, effective Jun. 1, 2017. Lanxess acquired the US chemical company in April 2017. The newly created position is limited to one year.

Forsyth has more than 35 years of management experience in the chemical industry. Since 2007 he has acted as EVP and CFO of Chemtura. Prior to that, he worked 27 years for the materials company Hexcel, holding various positions. There, he was appointed CFO in 1996, having previously worked as VP International Operations, heading up the business outside the United States. Forsyth holds an MBA from the London Business School.

Lanxess CEO Matthias Zachert said: “Stephen Forsyth brings exactly the qualities that Lanxess needs for integrating the Chemtura business: he has an excellent knowledge of the new businesses and employees and can also draw on longstanding experience in company transformation processes.”

Free Virtual Event

Sustainability in Bioprocessing
Bioprocess Forum

Sustainability in Bioprocessing

Join us to explore hot topics in sustainable bioprocessing like the industrial potential of enzymatic synthesis, innovative biocatalysis techniques, and the use of digital twins in bioprocessing.

Whitepaper

Excellence in Pharmaceutical Distribution and The Critical Role of Good Distribution Practice (GDP)
Setting the Standard

Excellence in Pharmaceutical Distribution and The Critical Role of Good Distribution Practice (GDP)

Are you ready to elevate your pharmaceutical operations? Download our exclusive whitepaper and discover how compliance with Good Distribution Practice (GDP) is essential for the safety and integrity of pharmaceuticals.